James D. Bowen
University of Washington
PsychiatryInternal medicineSurgeryCase-control studyOdds ratioPsychologyPhysical therapyPediatricsProspective cohort studyCohort studyHazard ratioDepression (differential diagnoses)DiseaseCentral nervous system diseaseDementiaMultiple sclerosisPopulationAlzheimer's diseaseRisk factorMedicineCohortGerontology
Publications 137
#1Bruce A.C. Cree (UCSF: University of California, San Francisco)H-Index: 66
#2James D. BowenH-Index: 63
Last. Thomas Leist (Thomas Jefferson University)H-Index: 22
view all 12 authors...
Abstract Background In the Phase 3, 96-week ORACLE-MS study, cladribine 10 mg tablets (3.5 mg/kg or 5.25 mg/kg cumulative dose over 2 years) significantly reduced the rate of conversion to clinically definite multiple sclerosis (CDMS) per the Poser criteria (henceforth referred to as CDMS), multiple sclerosis (MS) per the 2005 McDonald criteria, and the number of new or persisting T1 gadolinium-enhancing (Gd+), new or enlarging T2, and combined unique active (CUA) lesions versus placebo in parti...
2 CitationsSource
#1James D. Bowen (UW: University of Washington)H-Index: 63
#2Justine Brink (UW: University of Washington)H-Index: 1
Last. Pavle Repovic (UW: University of Washington)H-Index: 8
view all 7 authors...
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1
25 CitationsSource
#1James D. BowenH-Index: 63
#2Alan Gillett (Merck Serono)H-Index: 1
Last. Thomas Leist (Thomas Jefferson University)H-Index: 22
view all 7 authors...
Introduction In the Phase 3 ORACLE-MS trial in 616 subjects with a first demyelinating event at high risk of converting to multiple sclerosis (MS), treatment with cladribine tablets 10 mg (3.5 mg/kg or 5.25 mg/kg cumulative dose over 2 years [CT3.5 and CT5.25, respectively]) significantly delayed time to conversion to clinically definite multiple sclerosis (CDMS) according to Poser criteria (67% or 62% risk reduction [RR], respectively) and time to conversion to 2005 McDonald MS (50% or 57% RR, ...
#1James D. BowenH-Index: 63
#2Chris M. KozmaH-Index: 21
Last. Amy L. Phillips (Merck Serono)H-Index: 16
view all 4 authors...
BackgroundAdministrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings.ObjectiveTo evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide).MethodsPatients from an administrative claims database (1 Jan 2012–31 Dec 2015) were selected if they: were 18–63...
3 CitationsSource
#1George E. Georges (Fred Hutchinson Cancer Research Center)H-Index: 32
#2James D. Bowen (UW: University of Washington)H-Index: 63
Last. Richard A. NashH-Index: 71
view all 10 authors...
1 CitationsSource
1 CitationsSource
#1Christian D.E. Collins (Southampton General Hospital)H-Index: 1
#2Ben Ivry (Southampton General Hospital)H-Index: 1
Last. Ian Galea (University Hospital Southampton NHS Foundation Trust)H-Index: 24
view all 9 authors...
Background:Patient-Reported Expanded Disability Status Scale (PREDSS) tools are an attractive alternative to the Expanded Disability Status Scale (EDSS) during long term or geographically challenging studies, or in pressured clinical service environments.Objectives:Because the studies reporting these tools have used different metrics to compare the PREDSS and EDSS, we undertook an individual patient data level analysis of all available tools.Methods:Spearman’s rho and the Bland–Altman method wer...
32 CitationsSource
#1Elena Krutenkova (Tomsk State University)H-Index: 5
#2G. Aitmagambetova (Tomsk State University)H-Index: 1
Last. Vasily L. Yarnykh (Tomsk State University)H-Index: 36
view all 10 authors...
Myelin containing in basal ganglia in multiple sclerosis patients was evaluated using new noninvasive quantitative MRI method fast whole brain macromolecular proton fraction mapping. Myelin level in globus pallidus and putamen significantly decreased in multiple sclerosis patients as compared with healthy control subjects but not in substantia nigra and caudate nucleus.
1 CitationsSource
#1Vasily L. Yarnykh (UW: University of Wisconsin-Madison)H-Index: 36
#2James D. BowenH-Index: 63
Last. Lily K. Jung HensonH-Index: 2
view all 10 authors...
Whole-brain macromolecular proton fraction mapping enables quantitative assessment of demyelination in normal-appearing white and gray matter and better correlates with clinical status in multiple sclerosis than traditional magnetization transfer and R1 mapping.
46 CitationsSource
#1Fred D. Lublin (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 69
#2James D. BowenH-Index: 63
Last. Steven Fischkoff (Celgene)H-Index: 5
view all 11 authors...
Abstract Background Infusion of PDA-001, a preparation of mesenchymal-like cells derived from full-term human placenta, is a new approach in the treatment of patients with multiple sclerosis. Objective This safety study aimed to rule out the possibility of paradoxical exacerbation of disease activity by PDA-001 in patients with multiple sclerosis. Methods This was a phase 1b, multicenter, randomized, double-blind, placebo-controlled, 2-dose ranging study including patients with relapsing-remitti...
66 CitationsSource